HU191598B - Method for the preparation of injection solution suitable preferably against cathosis - Google Patents
Method for the preparation of injection solution suitable preferably against cathosis Download PDFInfo
- Publication number
- HU191598B HU191598B HU841091A HU109184A HU191598B HU 191598 B HU191598 B HU 191598B HU 841091 A HU841091 A HU 841091A HU 109184 A HU109184 A HU 109184A HU 191598 B HU191598 B HU 191598B
- Authority
- HU
- Hungary
- Prior art keywords
- nicotinic acid
- weight
- glucose
- percent
- ketosis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000007924 injection Substances 0.000 title claims description 3
- 238000002347 injection Methods 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title claims description 3
- 239000000243 solution Substances 0.000 title description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 25
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 25
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 18
- 239000008103 glucose Substances 0.000 claims abstract description 18
- 208000007976 Ketosis Diseases 0.000 claims abstract description 14
- 230000004140 ketosis Effects 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000654 additive Substances 0.000 claims abstract description 9
- 230000000996 additive effect Effects 0.000 claims abstract description 7
- 229940102223 injectable solution Drugs 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 abstract description 17
- 208000010706 fatty liver disease Diseases 0.000 abstract description 5
- 208000004930 Fatty Liver Diseases 0.000 abstract description 4
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 229910052783 alkali metal Inorganic materials 0.000 abstract description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 abstract description 2
- 229940035024 thioglycerol Drugs 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- UOULCEYHQNCFFH-UHFFFAOYSA-M sodium;hydroxymethanesulfonate Chemical compound [Na+].OCS([O-])(=O)=O UOULCEYHQNCFFH-UHFFFAOYSA-M 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004470 DL Methionine Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HRKQOINLCJTGBK-UHFFFAOYSA-L dioxidosulfate(2-) Chemical compound [O-]S[O-] HRKQOINLCJTGBK-UHFFFAOYSA-L 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- -1 vitamin B 6 Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU841091A HU191598B (en) | 1984-03-20 | 1984-03-20 | Method for the preparation of injection solution suitable preferably against cathosis |
| DE19853505572 DE3505572A1 (de) | 1984-03-20 | 1985-02-18 | Injizierbare loesung, besonders zur behandlung von ketose, und verfahren zur herstellung derselben |
| BE1/11215A BE901959A (fr) | 1984-03-20 | 1985-03-18 | Solution injectable, notamment pour le traitement de la cetose et son procede de preparation. |
| FR8504016A FR2561522B1 (fr) | 1984-03-20 | 1985-03-19 | Solution injectable, notamment pour le traitement de la cetose et son procede de preparation |
| GB08507176A GB2157561B (en) | 1984-03-20 | 1985-03-20 | An injectable solution especially for treating ketosis and a process for the preparation thereof |
| JP60054707A JPS60260510A (ja) | 1984-03-20 | 1985-03-20 | ケトン症治療用の注射溶液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU841091A HU191598B (en) | 1984-03-20 | 1984-03-20 | Method for the preparation of injection solution suitable preferably against cathosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT37035A HUT37035A (en) | 1985-11-28 |
| HU191598B true HU191598B (en) | 1987-03-30 |
Family
ID=10952793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU841091A HU191598B (en) | 1984-03-20 | 1984-03-20 | Method for the preparation of injection solution suitable preferably against cathosis |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS60260510A (OSRAM) |
| BE (1) | BE901959A (OSRAM) |
| DE (1) | DE3505572A1 (OSRAM) |
| FR (1) | FR2561522B1 (OSRAM) |
| GB (1) | GB2157561B (OSRAM) |
| HU (1) | HU191598B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2245491A (en) * | 1990-06-25 | 1992-01-08 | Medvet Science Pty Ltd | Inhibition of metabolic oxalate formation |
| DE9111598U1 (de) * | 1991-09-18 | 1993-01-28 | Helga Kellermann Mineralgetränke, 5063 Overath | Futtermittel |
| GB9216460D0 (en) * | 1992-08-03 | 1992-09-16 | Lilly Industries Ltd | Veterinary method |
| JP2990686B2 (ja) * | 1994-11-17 | 1999-12-13 | 田辺製薬株式会社 | 水溶性ビタミンｂ類配合総合輸液 |
| JP2001114681A (ja) * | 1999-10-18 | 2001-04-24 | Ajinomoto Co Inc | ケトーシス改善剤 |
| RU2238728C1 (ru) * | 2003-05-06 | 2004-10-27 | Открытое акционерное общество "Новосибхимфарм" | Способ получения раствора никотиновой кислоты для инъекций |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD60477A (OSRAM) * | ||||
| GB500770A (en) * | 1937-09-30 | 1939-02-15 | Vitamol Inc | Improvements in or relating to vitamin compositions for use in feeding poultry and livestock, and methods of making the same |
| FR1350101A (fr) * | 1962-12-13 | 1964-01-24 | Produit pour l'alimentation des animaux | |
| BE739613A (OSRAM) * | 1968-10-03 | 1970-03-02 | ||
| GB1289096A (OSRAM) * | 1968-10-03 | 1972-09-13 | ||
| ZA73288B (en) * | 1972-02-25 | 1973-10-31 | Hoffmann La Roche | Mineral salts containing preparation |
| AU7003774A (en) * | 1974-06-13 | 1975-12-18 | Otsuka Pharma Co Ltd | Parenteral feeding method |
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
-
1984
- 1984-03-20 HU HU841091A patent/HU191598B/hu not_active IP Right Cessation
-
1985
- 1985-02-18 DE DE19853505572 patent/DE3505572A1/de active Granted
- 1985-03-18 BE BE1/11215A patent/BE901959A/fr not_active IP Right Cessation
- 1985-03-19 FR FR8504016A patent/FR2561522B1/fr not_active Expired
- 1985-03-20 GB GB08507176A patent/GB2157561B/en not_active Expired
- 1985-03-20 JP JP60054707A patent/JPS60260510A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2561522B1 (fr) | 1988-10-14 |
| GB8507176D0 (en) | 1985-04-24 |
| GB2157561B (en) | 1988-01-20 |
| HUT37035A (en) | 1985-11-28 |
| DE3505572A1 (de) | 1985-09-26 |
| GB2157561A (en) | 1985-10-30 |
| DE3505572C2 (OSRAM) | 1989-04-20 |
| BE901959A (fr) | 1985-09-18 |
| FR2561522A1 (fr) | 1985-09-27 |
| JPS60260510A (ja) | 1985-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9327028B2 (en) | Acetylcysteine compositions and methods of use thereof | |
| ALEXANDER et al. | A new model for studying nutrition in peritonitis: the adverse effect of overfeeding | |
| US5431925A (en) | Nutritive composition for prevention and therapy of infection diseases caused by immunosuppression | |
| KuKanich et al. | Effect of formulation and route of administration on tissue residues and withdrawal times | |
| HU186296B (en) | Process for producing parenteral pharmaceutical compositions | |
| KR20020022794A (ko) | 일반 염을 함유하는 목시플록사신 제형 | |
| KR880005933A (ko) | 비타민 b6-함유 약제학적 제제 | |
| HU191598B (en) | Method for the preparation of injection solution suitable preferably against cathosis | |
| US4185093A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
| US3943250A (en) | Method and pharmaceutical preparations for treating and preventing physiological disturbances in vertebrates, caused by molds and yeasts | |
| US4689319A (en) | Oral energy rich therapy for diarrhea in mammals | |
| US20150351428A1 (en) | Methods and compositions for orally dosing postnatal swine | |
| JP2780994B2 (ja) | フェネタノールアミンと成長ホルモンとの組成物 | |
| KR20140047617A (ko) | 마크로사이클릭 락톤 및 레바미솔을 포함하는 항-기생충 조성물 및 기생충 감염의 치료 방법 | |
| DE3115322A1 (de) | Oral zu verabreichendes, pharmazeutisch bzw. diagnostisch oder als nahrungsmittelzusatz wirksames bzw. verwendbares mittel | |
| US20220079979A1 (en) | Aqueous composition for livestock animals | |
| US3655882A (en) | Stable dietary supplement for new born pigs | |
| DE2733578A1 (de) | Intravenoese mittel, verfahren zu deren herstellung sowie deren verwendung | |
| US4430329A (en) | Synergistic treatment of adult canine heartworm with thiacetarsamide and ivermectin | |
| MXPA02006169A (es) | Metodo para mejorar la capacidad de eclosion de huevos. | |
| EP0245105A1 (en) | Veterinary composition | |
| KR102586244B1 (ko) | 카르니틴, 비타민 b군, 비타민 e, 셀레늄, 및 글리세린을 이용한 케토시스 치료방법 | |
| KR102058133B1 (ko) | 혼합제제 내 항생제 용해도를 향상시킬 수 있는 면역 증강용 조성물 및 이의 용도 | |
| McDonald | Summary of medications for use in psittacine birds | |
| Wieriks et al. | Animal Reactions to, and Tolerance of, two Local Anesthetic-free Tetracycline Preparations Injected by Various Routes A Comparison of Vendarcin® with Rolitetracycline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |